Effect of Erzhi Hegan Decoction on PD-1/PD-L1 Expression in Chronic Hepatitis B Patients with &quot;liver depression and kidney deficiency&quot;

doi:10.3969/j.issn.1005-0264.2023.004.005

PDF(3067 KB)

Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases ›› 2023, Vol. 33 ›› Issue (4) : 307-310. DOI: 10.3969/j.issn.1005-0264.2023.004.005

Effect of Erzhi Hegan Decoction on PD-1/PD-L1 Expression in Chronic Hepatitis B Patients with "liver depression and kidney deficiency"

DING Yue-ping¹, SHI Wei-qun^1,2△, LUO Shui-rong³, et al

Author information +

History +

Abstract

Objective: To observe the effect of Erzhi Hegan decoction combined with entecavir on the expression of PD-1/PD-L1 on the surface of CD4⁺ T cells in peripheral blood of patients with chronic hepatitis B of "liver depression and kidney deficiency" type. Methods: :A total of 59 patients with chronic hepatitis B were randomly divided into traditional Chinese medicine group (29 cases) and control group (30 cases). The traditional Chinese medicine(TCM) group was treated with Erzhi Hegan Decoction plus ETV,while the control group was treated with ETV only. Before treatment,24 weeks after treatment and 48 weeks after treatment,the expression level of ALT,Immunological markers of hepatitis B virus ,HBV DNA and PD-1/PD-L1 on CD4⁺ T cells were detected. Results: Compared with their baseline values,PD-1/PD-L1 expression levels on the surface of CD4⁺ T cells in peripheral blood of patients in both groups were significantly down-regulated compared with the baseline at 24 and 48 weeks of treatment (P<0.01). There was no significant difference in the expression level of PD-1/PD-L1 on the surface of CD4⁺ T cells between the two groups before and 24 weeks after treatment (P>0.05); after 48 weeks of treatment,the expression level of PD-1/PD-L1 on the surface of CD4⁺ T cells in the treatment group was significantly lower than that in the control group (P<0.05). After 24 and 48 weeks of treatment,the negative rate of HBV DNA in TCM group was significantly higher than that in control group (P<0.05). ALT normalization rate was higher in both groups (P>0.05). Conclusion: Erzhi Hegan decoction can break the immune tolerance of the body by affecting the expression level of PD-1/PD-L1 on the surface of CD4⁺ T cells,so as to improve the immune mechanism of the body and enhance the antiviral ability.

Key words

Erzhi Hegan Decoction / Hepatitis B / Immunoregulation / PD-1 / PD-L1

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

DING Yue-ping, SHI Wei-qun, LUO Shui-rong, et al. Effect of Erzhi Hegan Decoction on PD-1/PD-L1 Expression in Chronic Hepatitis B Patients with "liver depression and kidney deficiency"[J]. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 2023, 33(4): 307-310 https://doi.org/10.3969/j.issn.1005-0264.2023.004.005

References

[1]Global Hepatitis Report 2017.Geneva:World Health Organizati-on[C].2017.Licence:CC BY-NC-SA 3.0 IGO.
[2]Liu J,Liang W,Jing W,et al.Countdown to 2030:eliminating hepatitis B disease,China[J].Bull World Health Organ,2019,97(3):230-238.
[3]张林,方峰.慢性乙型肝炎相关PD-1抑制性信号通路研究进展[J].中国免疫学杂志,2019,35(19):2419-22,29.
[4]Bertoletti A,Ferrari C.Innate and adaptive immune responses in chronic hepatitis B virus infections:towards restoration of immune control of viral infection[J].Gut,2012,61(12):1754-1764.
[5]Fisicaro P,Valdatta C,Massari M,et al.Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B[J].Gastroenterology,2010,138(2):682-693.
[6]谢冬英,林炳亮,陈凤娟,等.慢性乙型肝炎患者抗病毒治疗过程中程序性死亡分子1及其配体表达的变化[J].中华肝脏病杂志,2010,18(9):646-650.
[7]华忠,顾锡炳,陆忠华,等.慢性乙型肝炎患者血清HBV DNA水平与细胞毒性T淋巴细胞表面PD-1表达的关系和意义[J].中华实验和临床病毒学杂志,2014,28(4):255-257.
[8]Yang HI Lu SN,Liaw YF,et al.Hepatitis B e antigen and the risk of hepatocellular carcinoma[J].N Engl J Medicine,2002,347(3):168-174.
[9]Lau GK,Wang FS.Uncover the immune biomarkers underlying hepatitis B e antigen (HBeAg) seroconversion: A need for more translational study[J]. J Hepatol,2012,56(4):753-755.
[10]Ma H,Zhang HH,Wei L.Frequency of T-cell FoxP3+ Treg and CD4⁺/CD8⁺ PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon[J].Chin Med J(Engl),2013,126(2):267-273.
[11]李跃文,王博龙.二至丸抗肝纤维化活性成分-靶点-通路的网络预测[J].中国实验方剂学杂志,2018,24(11):201-205.
[12]姚卫峰,蒋叶娟,蔡秀江,等.二至丸对四氯化碳致大鼠急性肝损伤血浆代谢组学研究[J].中国药学杂志,2013,48(10):808-813.
[13]王进进,奚香君,王頔,等.二仙汤与二至丸对小鼠生殖内分泌和免疫系统调节作用的比较研究[J].江苏中医药,2013,45(8):73-75.
[14]周步高,刘馥春,刘妙华,等.论柴胡、芍药在柴胡疏肝散中的核心地位[J].中国中医基础医学杂志,2020,26(1):101-102,105.
[15]严鸣光,钟芳芳,郭建军,等.白芍总苷对自身免疫性肝炎大鼠免疫调节机制的研究[J].中华生物医学工程杂志,2018,24(5):324-327.
[16]陈琦,陈素红,吕圭源,等.芍药提取物对老年自发性高血压大鼠血压、血脂以及肝功能的影响[J].浙江中医药大学学报,2013,37(2):187-192.
[17]孙文平,李发胜,侯殿东,等.当归、白术、制白附子多糖对小鼠免疫调节作用的影响[J].中国中医药信息杂志,2008,15(7):37-38.
[18]袁晓旭,杨明明,赵桂琴,等.郁金化学成分及药理作用研究进展[J].承德医学院学报,2016,33(6):487-489.
[19]孙蕾,张红霞,孙静秋,等.赶黄草中肝脏保护作用化学成分的分离与鉴定[J].武警后勤学院学报(医学版),2018,27(7):580-584.
[20]王亮,吴晓枫,宋薇,等.真实世界研究和RCT随机对照研究方法评价中西医结合干预慢性乙型肝炎疗效[J].浙江中医药大学学报,2020,44(10):980-985.

PDF(3067 KB)

666

Accesses

Citation

Detail

Sections

Recommended

Abstract
Key words
Cite this article
References

Please choose a citation manager

Content to export

Abstract

Key words

Cite this article

{{custom_sec.title}}

{{custom_sec.title}}

References

{{custom_fnGroup.title_en}}

Footnotes

Received
2021-08-04
Issue Date
2024-02-26

模态框（Modal）标题

Please choose a citation manager

Content to export

Abstract

Key words

Cite this article

{{custom_sec.title}}

{{custom_sec.title}}

References

{{custom_fnGroup.title_en}}

Footnotes